Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 7
Submit an article Journal homepage
72
Views
19
CrossRef citations to date
0
Altmetric
Review

Current synthetic inhibitors of human neutrophil elastase in 2005

Hiroyuki Ohbayashi Internal Medicine, Tohno-Kousei Hospital, 76-1, Toki-cho, Mizunami City, Gifu Pref. 509-6101, Japan. [email protected]
Pages 759-771 | Published online: 13 Jul 2005

Bibliography

  • JANOFF A, BLONDIN J: The effect of human granulocyte elastase on bacterial suspensions. Lab. Invest. (1973) 29(4):454.
  • SANDHAUS RA: Elastase may play a central role in neutrophil migration through connective tissue. In: Pulmonary emphysema and proteolysis Taylar JC, Mittman C (Eds), New York Academic Press, USA (1987):227–233.
  • BIETH G: Elastase: catalytic and biological properties. In: Regulation of matrix accumulation. Mecham RP (Eds), Academic Press, NY, USA (1986):217–306.
  • TRAVIS J, DUBIN A, POTEMPA J, WATOREK W, KURDOWSKA A: Neutrophil proteinases. Ann. NY Acad. Sci. (1991) 624:81–86.
  • FARLEY D, FALLER B, NICK H: Therapeutic protein inhibitors of elastase. Drugs Pharm. Sci. (1997) 84:305–335.
  • •A comphrehensive review of therapeutic properties of elastase inhibitor.
  • BINGLE L, TETLEY TD: Secretory leukoprotease inhibitor: partnering al-proteinase inhibitor to combat pulmonary inflammation. Thorax (1996) 51(12):1273–1274.
  • TETLEY TD: New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax (1993) 48(5):560–565.
  • LEE WL, DOWNEY GP: Leukocyte elastase: physiological functions and role in acute lung injury. Am. I Respir: Grit. Care Med. (2001) 164(5):896–904.
  • ••A comphrehensive review of HNE in ALTand ARDS.
  • KAWABATA K, HAGIO T, MATSUOKA S: The role of neutrphil elastase in acute lung injury. Eur. Pharmacol (2002) 451(1):1–10.
  • ••A thorough review of HNE in ALT.
  • TAMAKUMA S, OGAWA M, AIKAWA N et al.: Relationship between neutrophil elastase and acute lung injury in humans. Pulm. Pharmacol Ther. (2004) 17(5):271–279.
  • HIEMSTRA PS, VAN WETERING S, STOLK J: Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur. Respir: J. (1998) 12(5):1200–1208.
  • BARNS PJ: Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir: Grit. Care Med. (1999) 160(5, Pt.2):572–579.
  • ••A comphrehensive review of new treatmentof COPD.
  • BIRRER P: Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies. Respiration. (1995) 62\(Supp1.1):25–28.
  • BALFOUR-LYNN IM: The protease-antiprotease battle in the cystic fibrosis lung. J. R. Soc. Med. (1999) 92\(Supp1.37):23–30.
  • OHBAYASHI H: The pathophysiological contributions of neutrophils and neutrophil elastase to asthma. In: Focus on Asthma Research. Miroslav Tersa (Ed.), Nova Medical Books, New York, USA (2004):67–125.
  • •A thorough review of the pathogic contributions of HNE in asthma.
  • ROYSTON D: Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. Cardiovasc. Pharmacol (1996) 27\(Supp1.1):542–549.
  • EDMUNDS LH JR: Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. (1998) 66 (Supp1.5):S12–S16.
  • •A thorough review of the pathogic contributions of HNE in cardiopulmonary bypass.
  • IMAKI K, OKADA T, NAKAYAMA Y et al.: Non-peptidic inhibitors of human neutrophil elastase: the design and synthesis of sulfonanilide-containing inhibitors. Bioorg. Med. Chem. (1996) 4(12):2115–2134.
  • KAWABATA K, SUZUKI M, SUGITANI M, IMAKI K, TODA M, MIYAMOTO T: ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. (1991) 177(2):814–820.
  • YASUI S, NAGAI A, AOSHIBA K, OZZAWA Y, KAKUTA Y, KONNO K: A specific neutrophil elastase inhibitor (ONO-5046.Na) attenuates LPS-induced acute lung inflammation in the hamster. Eur. Respir. J. (1995) 8(8):1293–1299.
  • MURAKAMI K, OKAJIMA K, UCHIBA M et al: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. (1996) 87(2):642–647.
  • MURAKAMI K, OKAJIMA K, UCHIBA M, OKABE H, TAKATSUKI K: Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Grit. Care Med. (1996) 24(6):1047–1053.
  • HAGA Y, OGAWA M: Neutrophil elastase inhibitor (ONO-5046.Na) decreases production of proinflammatory cytokines by lipopolysaccharide-stimulated human monocytes. Res. Commun. Mol Pathol Pharmacol (1997) 98(3):243–248.
  • ISHII K, ITO Y, KATAGIRI H, MATSUMOTO Y, KAKITA A, MAJIMA M: Neutrophil elastase inhibitor attenuates lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock (2002) 18(2):163–168.
  • WANG HG, SHIBAMOTO T, MIYAHARA T et al: Effect of ONO-5046, a specific neutrophil elastase inhibitor, on the phorbol myristate acetate-induced injury in isolated dog lung. Exp. Lung Res. (1999) 25(1):55–67.
  • TAOOKA Y, MAEDA A, HIYAMA K, ISHIOKA S, YAMAKIDO M: Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am. Respir: Crit. Care Med. (1997) 156(1):260–265.
  • SAKAMAKI F, ISHIZAKA A, URANO T et al: Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am. I Respir: Grit. Care Med. (1996) 153(1):391–397.
  • NISHINA K, MIKAWA K, TAKAO Y, MAEKAWA N, SHIGA M, OBARA H: ONO-5046, an elastase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth. Analg. (1997) 84(5):1097–1103.
  • KINOSHITA M, ONO S, MOCHIZUKI H: Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur. Surg. Res. (2000) 32(6):337–346.
  • KUBO K, KOBAYASHI T, HAYANO T et al: Effects of ONO-5046, a specific neutrophil elastase inhibitor, on endotoxin-induced lung injury in sheep. I Appl. Physiol (1994) 77(3):1333–1340.
  • HAGIO T, NAKAO S, MATSUOKA H, MATSUMOTO S, KAWABATA K, OHNO H: Inhibition of neutrophil elastase activity attenuates complement-mediated lung injury in the hamster. Eur. Pharinacol (2001) 426(1-2):131–138.
  • YAMAGUCHI Y, MATSUMURA F, WANG FS et al: Neutrophil elastase enhances intercellular adhesion molecule-1 expression. Transplantation (1998) 65(12):1622–1628.
  • HAGIO T, MASTUMOTO S, NAKAO S, ABIRU T, OHNO H, KAWABATA K: Elastase inhibition reduced death associated with acid aspiration-induced lung injury in hamsters. Eur. Pharinacol (2004) 488(1-3):173–180.
  • ZEIHER BG, MATSUOKA S, KAWABATA K, REPINE JE: Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Grit. Care Med. (2002) 30\(Supp1.5):S281–S287.
  • •The preclinical and clinical evidence of sivelestat in ALT.
  • TAMAKUWA S, SHIBA T, HIRASAWA H et al.: A Phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients. I Clia Ther. Med. (1998) 14:289–318.
  • ZEIHER BG, ARTIGAS A, VINCENT JL et al.: STRIVE STUDY GROUP: Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Grit. Care Med. (2004) 32(8):1695–1702.
  • KADOI Y, HINOHARA H, KUNIMOTO F et al: Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth. Analg. (2004) 99(3):872–877.
  • FUJIMOTO K, KUBO K, SHINOZAKI S et al: Neutrophil elastase inhibitor reduces asthmatic responses in allergic sheep. Respir. Physic] (1995) 100(1):91–100.
  • TAKEYAMA K, TAMAOKI J, KONNO K, TAKIZAWA T: Effect of a neutrophil elastase inhibitor on NAP-1/ IL-8-induced stimulation of goblet cell secretion in guinea pig airways. Eur. Respir. J. (1994) 7\(supp1.18):765.
  • YOSHITAKE K, ISOHAMA Y, KAI H, TAKAHAMA K, MIYATA T: Substance P stimulates the loss of cell-associated high molecular weight glycoconjugates from cultured hamster tracheal epithelial cells through polymorphonuclear leucocytes activation. Biochem. Mol. Biol. Int. (1995) 36(5):1009–1116.
  • TAKAYAMA M, ISHIBASHI M, ISHII H, KURAKI T, NISHIDA T, YOSHIDA M: Effects of neutrophil elastase inhibitor (ONO-5046) on lung injury after intestinal ischemia-reperfusion. Appl. Physiol (2001) 91(4):1800–1807.
  • ISHIKAWA N, ODA M, KAWAGUCHI M, TSUNEZUKA Y, WATANABE G: The effects of a specific neutrophil elastase inhibitor (ONO-5046) in pulmonary ischemia-reperfusion injury. Transpl. Int. (2003) 16(5):341–346.
  • DOI K, HORIUCHI T, UCHINAMI M, TABO T et al.: Neutrophil elastase inhibitor reduces hepatic metastases induced by ischaemia-reperfusion in rats. Eur. 1 Surg. (2002) 168(8–9):507–510.
  • PRADELLA L: ONO-5046 Ono Pharmaceutical. Curr. Opin. Investig. Drugs. (1999) 1(5):485–501.
  • •A review concerning ONO-5046.
  • RIZZI M, CASALE E, CODA A et al.: Serine proteinase inhibition by cyclic thiolic compound Y53025: a crystallographic study. Biochein Int. (1992) 28(3):385–392.
  • CARUGO KD, RIZZI M, FASANO M et al: Inhibition of serine proteinases belonging to the chymotrypsin superfamily by the cyclic thiolic compound Y53025: a comparative crystallographic study. Biochem. Biophys. Res. Commun. (1993) 193(1):32–39.
  • LUISETTI M, PICCIONI PD, DONNINI M et al.: Studies of MR889, a new synthetic proteinase inhibitor. Biochem. Biophys. Res. Commun. (1989) 165(2):568–573.
  • BAICI A, PELLOSO R, HORLER D: The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochem Phartmacol (1990) 39(5):919–924.
  • LUISETTI M, STURANI C, SELLA D et al: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Resp. (1996) 9(7):1482–1486.
  • OHMOTO K, YAMAMOTO T, OKUMA M et al.: Development of orally active nonpeptide inhibitors of human neutrophil elastase. J. Med. Chem. (2001) 44:1268–1285.
  • OHMOTO K, OKUMURA M, YAMAMOTO T et al.: Design and synthesis of new orally active inhibitors of human neutrophil elastase. Bioorg. Med. Chem. (2001) 9(5):1307–1323.
  • OHMOTO K, YAMAMOTO T, HORIUCHI T et al.: Design and synthesis of new orally active non-peptide inhibitors of human neutrophil elastase. I Med. Chem. (2000) 43(26): 4927–4929.
  • KURAKI T, ISHIBASHI M, TAKAYAMA M, SHIRAISHI M, YOSHIDA M: A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Am. I Respir. Grit. Care Med. (2002) 166(4):496–500.
  • SEKIOKA T, HIROTA Y, NAKANO S et al.: Pharmacological profile of a novel orally active neutrophil elastase inhibitor, ONO-6818. Am. J. Grit. Care Med. (2001) 163:A597.
  • YOSHIMURA Y, HIRAMATSU Y, SATO Y et al.: ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation. Ann. Thorac. Surg. (2003) 76(4):1234–1239.
  • HIROTA Y, SUZUKI M, YAMAGUCHI K, FUJITA T, KATSUBE N: Effects of the neutrophil elastase inhibitor (ONO-6818) on acetic acid induced colitis in Syrian hamsters. Vet. Med. Sci. (2004) 66(10):1223–1228.
  • TRIFILIEFF A: ONO-6818 Cortech/Ono.Curr. Opia Invest. Drugs (2002) 3(8):1161–1164.
  • •A review concerning ONO-6818.
  • KUBO T, OKAZAKI H, KUROMIYA A et al.: AE-3763, a novel inhibitor of neutrophil elastase (1): biochemical and pharmacological properties of AE-3763. fpn. Pharmacol (2001) 85\(Supp1.1):P558.
  • KUROMIYA A, OKAZAKI H, KUBO T et al: AE-3763, a novel inhibitor of neutrophil elastase (2): effects of AE-3763 on acute organ failure models. fpn. Pharmacol (2001) 85 (Supp1.1):P559.
  • DELACOURT C, HERIGAULT S, DELCLAUX C et al.: Protein against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. Respir: Cell Mol Biol. (2002) 26:290–297.
  • DYAX CORP.: Press release (16 April 1997).
  • DELACOURT C, HERIGAULT S, DELCLAUX C et al.: Projection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. Respir. Grit. Care Med. (2001) 163\(Supp1.5): A490.
  • GRIMBERT D, VECELLIO L, DELEPINE P et al.: Characteristics of EPI-HNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J. Aerosol Med. (2003) 16(2):121–129.
  • DUBRAY C, SAUDUBRAY F, CLAVIEN H et al.: Phase I studies with a new human neutrophil elastase inhibitor, EPI-HNE-4, administered by inhalation in healthy volunteers. Am. I Respir. Grit. Care Med. (2001) 163\(Supp1.5):A564.
  • SAUDUBRAY F, LABBE A, WALLAERT B et al: Phase ha clinical study of a new human neutrophil elastase inhibitor (HNE), EPI-HNE4 (DX-890), with repeated administration by inhalation in adult cystic fibrosis patients. 26th Eur. Cyst. Fibros. Conference (2003) Abst. 85.
  • BRADBURY J: Neutrophil elastase inhibitors for cystic fibrosis. Drug Discov. Today (2001) 6(9):441–442.
  • DYAX CORP: Press release (24 February 2004).
  • DYAX CORP: Press release (27 April 2004).
  • HONORE S, ATTALAH HL, AZOULAY E et al: Beneficial effect on an inhibitor of leukocyte elastase (EPI-HNE-4) in presence of repeated lung injuries. Shock (2004) 22(2):131–136.
  • CARRELL RW, JEPPSSON JO, LAURELL CB et al: Structure and variation of human al-antitrypsin. Nature (1982) 298(5872):329–334.
  • HUBER R, CARRELL RW: Implications of the three-dimensional structure of a-1H-antitrypsin for structure and function of serpins. Biochemistry (1989) 28(23):8951–8966.
  • RENNARD SI, GHAFOURI M, THOMPSON AB et al: Fractional processing of sequential bronchoalveolar lavage to separate bronchial and alveolar samples. Am. Rev Respir: Dis. (1990) 141(1):208–217.
  • STOCKLEY RA, SHAW J, AFFORD SC, MORRISON HM, BUMETT D: Effect of al-proteinase inhibitor on neutrophil chemotaxis. Am. I Respir: Cell Mol Biol. (1990) 2(2):163–170.
  • BUCURENCI N, BLAKE DR, CHID WICK K, WINYARD PG: Inhibition of neutrophil superoxide production by human plasma al-antitrypsin. FEBS Lett. (1992) 300(1):21–24.
  • WENCKER M, FUHRMANN B, BANIK N, KONIETZKO N: Longitudinal follow-up of patients withal-protease inhibitor deficiency before and during therapy with IV with a1-protease inhibitor. Chest (2001) 19(3):737–744.
  • SANDHAUS R, STOCKS J, STOLLER J, GELMONT D, SUNDIN D, BRANTLY M: Phase I safety investigation of an aerosolized, recombinant al-antitrypsin in subjects with al-antitripsin deficiency. Eur. Resp. (2004) 24\(Supp1.48):Abst. 1509.
  • DHAMI R, GILKS B, XIE C, ZAY K, WRUGHT JL, CHURG A: Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by al-antitrypsin. Am. J. Respir: Cell Mol Biol. (2000) 22 (2): 244–252.
  • AYAD MS, KNIGHT KR, BURDON JG, BRENTON S: Secretory leukocyte proteinase inhibitor, a 1-antitrypsin deficiency and emphysema: preliminary study, speculation and an hypothesis. Respirology (2003) 8(2):175–180.
  • CHUNG A, WANG RD, XIE C, WRIGHT L: al-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am. I Res. Crit. Care Med. (2003) 168(2):199–207.
  • PEMBERTON PA, CANTWELL JS, WILK BJ et al.: Inhaled recombinant al-antitrypsin ameliorates cigarette-induced damage in the smoking mouse model. Eur. Respir: J. (2004) 24\(Supp1.48):1661
  • TOPPING JR, VANDEN BON EJ, TENNANT RC et al.: Effect of recombinant al antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP-9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstractive pulmonary disease (COPD). Eur. Respir. J. (2003) 22 (Supp1.45): 159.
  • GRATTON D, CANT WELL J, PEMBERTON P, BARR P, BARABE J, SUNDIN D: A study of the safety and tolerability of recombinant human al-antitrypsin (rAAT) gel in subjects with atopic dermatitis. J. Eur. Acad. Dermatol Venereol (2004) 18\(Supp1.2): FC07.15.
  • PROMETIC LIFE SCIENCE: Press release: (7 October 2004).
  • MOLHUIZEN HO, SCHALKWIJK J: Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol. Chem. Hoppe-Seyler. (1995) 376(1):1–7.
  • SALLENAVE JM, RYLE AP: Purification and investigation of elastase-specific inhibitor, a low molecular weight proteinase inhibitor from sputum. Am. Rev Respir. Dis. (1990) 141.A357.
  • WIEDOW 0, SCHRODER JM, GREGORY H, YOUNG JA, CHRISTOPHERS E: Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. .1 Biol. Chem. (1990) 265(25):14791–14795.
  • SALLENAVE JM, SILVA A: Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am. J. Respir. Cell Mol Biol. (1993) 8(4):439–445.
  • NARA K, ITO S, ITO T et al: Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed `cementoiff../. Biochem. (1994) 115(3):441–448.
  • TREMBLAY GM, SALLENAVE JM, ISRAEL-ASSAYAG E, CORMIER Y, GAULDIE J: Elafinielastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am. I Respir Cit. Care Med. (1996) 154(4, Pt.1):1092–1098.
  • SALLENAVE JM, SHULMANN J,98.CROSSLEY J, JORDANA M, GAULDIE J: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophific enzymes. Ain J. Respir Cell Mot. Biol. (1994) 11(6):733–741.
  • SALLENAVE JM: The role of secretory99.leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir. Res. (2000) 1(2):87–92.
  • TANAKA N, FUJIOKA A, TAJIMA S, ISHIBASHI A, HIROSE S: Elafin is induced in epidermis in skin disorders with100.dermal neutrophilic infiltration: IL-113 and tumour necrosis factor-a stimulate its secretion in vitro. BE J. Dermatol (2000) 143(4):728–732.
  • SUZUKI Y, FURUKAWA M, ABE J, KASHIWAGI M, HIROSE S: Localization of porcine trappin-2 (SKALP/elafin) in101.trachea and large intestine by in situ hybridization and immunohistochemistry. Histochem. Cell Biol. (2000) 114(1):15–20.
  • SIMPSON AJ, MAXWELL Al, GOVAN JR,loz.HASLETT C, SALLENAVE JM: Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS lett. (1999) 452(3):309–313.
  • MCMICHAEL J, MAXWELL A,103.HAYASHI K, TAYLOR K, DORIN J, SALLENAVE JM: The antimicrobial molecule elafin protects the lung against Staphylococcus aureus infection. Eur. Respir J. (2004) 24\(Supp1.48):186.
  • MEYER-HOFFERT U, WICHMANN N,104.SCHWICHTENBERG L, WHITE PC, WIEDO 0: Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp. Dermatol (2003) 12 (4):418–425.105.
  • CUNNINGHAM G, JAMES R, MCMICHAEL G, HASLETT C, SALLENNAVE JM: The antimicrobial molecule elafin up-regulates innate immune responses in mice lungs following bacterial106.lipopolysaccharide challenge; a transgenic approach. Clin. Invst. Med. (2004) 274\(Supp1.4):M3.9.
  • VAN WETERING S, VAN DER LINDEN AC, VAN STERKENBURG MA et al: Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. Investig. Med. (2000) 48(5):359–366.
  • REID PT, MARSDEN ME, CUNNINGHAM GA, HASLETT C, SALLENAVE JM: Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in Type II alveolar epithelial cells. FEBS Lett. (1999) 457(1):33–37.
  • HENRIKSEN PA, HITT M, XING Z et al.: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-KB-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. Immunol (2004) 172(7):4535–4544.
  • BAROLET AW, NILI N, CHEEMA A et al: Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler. Thromb. Vasc. Biol. (2001) 21(8):1269–1274.
  • ZAIDI SH, YOU XM, CIURA S, HUSAIN M, RABINOVITCH M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation (2002) 105(4):516–521.
  • ZWIERZCHONIEWASKS M, ROBBINS RC, RABINOVITCH M, FED OSEYEVA EV: Overexpression of elafin, a serine elastase-specific inhibitor, prevents acute cardiac allograft rejection. Am. J. Trans. (2004) 4\(Supp1.8):868.
  • TOMEE JF, KOETER GH, HIEMSTRA PS, KAUFFMAN HF: Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax (1998) 53(2):114–116.
  • DOUMAS S, KOLOLOTRONIS A, STEFANOPOULOS P: Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect. Immun. (2005) 73(3):1271–1274.
  • SALLENAVE JM, SI-TA HARM, COX G, CHIGNARD M, GAULDIE J: Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. j Leukoc. Biol. (1997) 61(6):695–702.
  • VAN WETERING S, VAN DER LINDEN AC, VAN STERKENBYRG MA, RABE KF, SCHALKWIJK J, HIEMSTRA PS: Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. Investig. Med. (2000) 48(5):359–366.
  • SAITOH H, MASUDA T, SHIMURA S, FUSHIMI T, SHIRATO K: Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am. J. Physiol Lung Cell Mol Physiol (2001) 280(1)179–87.
  • BINGLE L, TETLEY TD: Secretory leukoprotease inhibitor: partnering al-proteinase inhibitor to combat pulmonary inflammation. Thorax (1996) 51(12):1273–1274.
  • WRIGHT CD, HAVILL AM, MIDDLETON SC et al: Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J. Pharmacol Exp. Ther. (1999) 289(2):1007–1014.
  • SUZUKI T, WANG W, LIN JT, SHIRATO K, MITSUHASHI H, INOUE H: Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am. J. Respir. Grit. Care Med. (1996) 153(4, Pt.1):1405–1411.
  • Genomics-based Drug Data Rep. Regen. Ther. (2002) 2(6):345.
  • UEHARA A, MURAMOTO K, TAKADA H, SUGAWARA S: Neutrophil serine proteinases activate human nonepithelial cells to produce inflammatory cytokines through protease-activated receptor 2. J. Immunol (2003) 170(11):5690–5696.
  • COTTRELL GS, COELHO AM, BUNNETT NW: Protease-activated receptors: the role of cell-surface proteolysis in signalling. Essays Biochem. (2002) 38:169–183.
  • COUGHLIN SR, CAMERER E: Participation in inflammation. I Clin. Investig. (2003) 111:25–27.
  • D'ANDREA MR, DERIAN CK, LETURCQ D et al: Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. Histochem. Cytochem. (1998) 46(2):157–164.
  • COELHO AM, OSSOVSKAYA V, BUNNETT NW: Proteinase-activated receptor-2: physiological and pathophysiological roles. Curr. Med. Chem. Cardiovasc. Hematol Agents (2003) 1(1):61–72.
  • KNIGHT DA, LIM S, SCAFFIDI AK et al.: Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. I Allergy Chit. Immunol (2001) 108(5):797–803.
  • BOLTON SJ, MCNULTY CA, THOMAS RJ, HEWITT CR, WARDLAW AJ: Expression of and functional responses to protease-activated receptors on human eosinophils. Leukoc. Biol. (2003) 74(1):60–68.
  • SCHMIDLIN F, AMADESI S, DABBAGH K et al: Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway../. Immunol (2002) 169(9):5315–5321.
  • LINDER JR, KAHN ML, COUGHLIN SR et al: Delayed onset of inflammation in protease-activated receptor-2-deficient mice. J. Immunol (2000) 165(11):6504–6510.
  • KAWAGOE J, TAKIZAWA T, MATSUMOTO J et al.: Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. fpn. Pharmacol (2000) 88(1):77–84.
  • OHBAYASHI H: Current synthetic inhibitors of human neutrophil elastase. Expert Opin. Ther. Patents (2002) 12(1):65–84.

Websites

  • wwww.dailydrugnews.com Daily Essentials (15 April 2004).
  • www.dailydrugnews.com Daily Essentials (18 December 2003).
  • www.dailydrugnews.com Daily Essentials (3 March 2004).
  • www.dailydrugnews.com Daily Essentials (13 October 2003).
  • www.dailydrugnews.com Daily Essentials (19 July 2004). Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.